TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,697
Mkt Cap
$6.74T
Volume
2.33M
52W High
$15.69
52W Low
$12.80
PE Ratio
45.24
TAK Fundamentals
Price
$13.09
Prev Close
$13.77
Open
$13.28
50D MA
$14.68
Beta
0.28
Avg. Volume
2.83M
EPS (Annual)
$0.2242
P/B
0.91
Rev/Employee
$633,289.19
Loading...
Loading...
News
all
press releases
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer...
Business Wire·10h ago
News Placeholder
More News
News Placeholder
HyHub and HyHub Duo Devices Now Available in the U.S. to Simplify HYQVIA Infusion Preparation
Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are...
Business Wire·3d ago
News Placeholder
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and...
Business Wire·9d ago
News Placeholder
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market Innovent Biologics Announces Global...
PR Newswire·9d ago
News Placeholder
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Zacks·4mo ago
News Placeholder
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
Zacks·4mo ago
News Placeholder
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·4mo ago
News Placeholder
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Zacks·4mo ago
News Placeholder
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Zacks·5mo ago
News Placeholder
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
Zacks·5mo ago

Latest TAK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.